SEC Form 4 · accession 0001683168-26-007159
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert J Bitterman
Officer — Chairman, Pres. & CEO · Director
Period of report
Sep 11, 2026
Accepted (ET)
Sep 15, 2026 · 4:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001533040
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $.0001 par valueF2 | Sep 11, 2026 | F | 68,550 | $1.03 | D | 362,871 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold.
- F2Includes shares of common stock underlying unvested restricted stock units.